Friday, January 22, 2016
Alembic Pharmaceuticals has reported a whopping 281.2 per cent growth in its consolidate net profit at Rs 269.5 crore for the third quarter ended December 31, 2015 buoyed by US business. The company had registered consolidate net profit of Rs 70.66 crore in the corresponding quarter last year, the company said in a filing to the Bombay Stock Exchange. Revenue shot up 81 per cent to Rs 921.7 crore during the quarter compared to Rs 511.8 crore in same quarter last fiscal aided by exports. International business has registered a 248 percent year-on-year growth at Rs 521 crore with India branded business growing 15 per cent and API business showing 24 percent growth. The company said specialty segment among India business grew by 22 per cent with Tellzy becoming the fastest growing Telmisartan brand, adding India generics business declined 40 percent to Rs 20 crore. Meanwhile, shares of the company closed trading at Rs 625.65 apiece, up 6.48 per cent from the previous close on BSE.